A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative ...

EGFR Non-Small Cell Lung Cancer Market · GlobeNewswire Inc. The report offers comprehensive insights including market size, ...

Patients with operable non-small cell lung cancer (NSCLC) had significantly longer event-free survival (EFS) with ...

The non-small cell lung cancer clinical trial analysis report delivers important insights into ongoing research of 120+ ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. The Boston biotech has decided to discontinue a phase 1/2 trial in advanced KRAS G12C-mutated ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) ...

A large randomized trial in China found that adding the PD-L1 inhibitor adebrelimab to perioperative chemotherapy significantly improved event-free and overall survival in patients with resectable ...

The field of lung cancer research has increasingly turned its attention to the tumor immune microenvironment (TIME) in non-small cell lung cancer (NSCLC), ...

New findings of an Alliance Foundation Trials study show combining immunotherapy and chemotherapy before surgery improves ...

Zoldonrasib ideal for further evaluation in KRAS G12D-mutant disease, expert says ...

ANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer -- Commercial availability achieved within two months of announcing MENA ...

Accelerated approval expands zongertinib from post–systemic therapy (Aug 2025) into the untreated setting for HER2 (ERBB2) TKI-domain activating mutation–positive non-squamous NSCLC. A 76% objective ...